Cargando…

Childhood Hypercalciuric Hypercalcemia With Elevated Vitamin D and Suppressed Parathyroid Hormone: Long-Term Follow Up

Purpose: Hypercalcemia with low parathyroid hormone (PTH) level, hypercalciuria, nephrocalcinosis, or nephrolithiasis, was recently reported as caused by mutations in CYP24A1 and SLC34A genes. These encode for vitamin D-24A-hydroxylase and for the renal phosphate transporters NaPiIIa and NaPiIIc, re...

Descripción completa

Detalles Bibliográficos
Autores principales: Gurevich, Evgenia, Levi, Shelly, Borovitz, Yael, Alfandary, Hadas, Ganon, Liat, Dinour, Dganit, Davidovits, Miriam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631469/
https://www.ncbi.nlm.nih.gov/pubmed/34858904
http://dx.doi.org/10.3389/fped.2021.752312
_version_ 1784607567704489984
author Gurevich, Evgenia
Levi, Shelly
Borovitz, Yael
Alfandary, Hadas
Ganon, Liat
Dinour, Dganit
Davidovits, Miriam
author_facet Gurevich, Evgenia
Levi, Shelly
Borovitz, Yael
Alfandary, Hadas
Ganon, Liat
Dinour, Dganit
Davidovits, Miriam
author_sort Gurevich, Evgenia
collection PubMed
description Purpose: Hypercalcemia with low parathyroid hormone (PTH) level, hypercalciuria, nephrocalcinosis, or nephrolithiasis, was recently reported as caused by mutations in CYP24A1 and SLC34A genes. These encode for vitamin D-24A-hydroxylase and for the renal phosphate transporters NaPiIIa and NaPiIIc, respectively. We aimed to describe the clinical course of these monogenic disorders in patients with and without found mutations during long-term follow-up. Methods: Ten patients with hypercalcemia, hypercalciuria, elevated 1,25-(OH)(2)D levels and suppressed PTH were followed in our center during 1998–2019. Relevant laboratory and imaging data and results of genetic evaluation were retrieved from medical files. Results: The median age at presentation was 9.5 months (range 1 month−11 years), six were males, and the median follow-up time was 3.8 (1.1–14) years. Mutations in CYP24A1 and SLC34A3 were identified in three and one patients, respectively. Five patients presented with nephrocalcinosis, three with nephrolithiasis, and two had normal renal ultrasound. High blood calcium and 1,25-(OH)(2)D levels at presentation decreased during follow-up [11.1 ± 1 vs. 9.9 ± 0.5 mg/dl (p = 0.012), and 307 ± 130 vs. 209 ± 65 pmol/l (p = 0.03), respectively]; this paralleled an increase in suppressed PTH levels (5.8 ± 0.9 vs. 11.8 ± 7.3 pg/ml, p = 0.2). Substantial improvements in hypercalciuria and renal sonography findings were not observed. Two patients had impaired renal function (eGFR 84–88 ml/min/1/73 m(2)) at the last follow up. Interventions included appropriate diet, citrate supplementation, and thiazides. Conclusion: Despite improvement in hypercalcemia and 1,25-(OH)(2)D levels, not all the patients showed improvements in hypercalciuria and nephrocalcinosis. Deterioration of renal function was also observed. Long-term follow up and intervention to prevent nephrocalcinosis and nephrolithiasis are recommended in these children.
format Online
Article
Text
id pubmed-8631469
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86314692021-12-01 Childhood Hypercalciuric Hypercalcemia With Elevated Vitamin D and Suppressed Parathyroid Hormone: Long-Term Follow Up Gurevich, Evgenia Levi, Shelly Borovitz, Yael Alfandary, Hadas Ganon, Liat Dinour, Dganit Davidovits, Miriam Front Pediatr Pediatrics Purpose: Hypercalcemia with low parathyroid hormone (PTH) level, hypercalciuria, nephrocalcinosis, or nephrolithiasis, was recently reported as caused by mutations in CYP24A1 and SLC34A genes. These encode for vitamin D-24A-hydroxylase and for the renal phosphate transporters NaPiIIa and NaPiIIc, respectively. We aimed to describe the clinical course of these monogenic disorders in patients with and without found mutations during long-term follow-up. Methods: Ten patients with hypercalcemia, hypercalciuria, elevated 1,25-(OH)(2)D levels and suppressed PTH were followed in our center during 1998–2019. Relevant laboratory and imaging data and results of genetic evaluation were retrieved from medical files. Results: The median age at presentation was 9.5 months (range 1 month−11 years), six were males, and the median follow-up time was 3.8 (1.1–14) years. Mutations in CYP24A1 and SLC34A3 were identified in three and one patients, respectively. Five patients presented with nephrocalcinosis, three with nephrolithiasis, and two had normal renal ultrasound. High blood calcium and 1,25-(OH)(2)D levels at presentation decreased during follow-up [11.1 ± 1 vs. 9.9 ± 0.5 mg/dl (p = 0.012), and 307 ± 130 vs. 209 ± 65 pmol/l (p = 0.03), respectively]; this paralleled an increase in suppressed PTH levels (5.8 ± 0.9 vs. 11.8 ± 7.3 pg/ml, p = 0.2). Substantial improvements in hypercalciuria and renal sonography findings were not observed. Two patients had impaired renal function (eGFR 84–88 ml/min/1/73 m(2)) at the last follow up. Interventions included appropriate diet, citrate supplementation, and thiazides. Conclusion: Despite improvement in hypercalcemia and 1,25-(OH)(2)D levels, not all the patients showed improvements in hypercalciuria and nephrocalcinosis. Deterioration of renal function was also observed. Long-term follow up and intervention to prevent nephrocalcinosis and nephrolithiasis are recommended in these children. Frontiers Media S.A. 2021-11-10 /pmc/articles/PMC8631469/ /pubmed/34858904 http://dx.doi.org/10.3389/fped.2021.752312 Text en Copyright © 2021 Gurevich, Levi, Borovitz, Alfandary, Ganon, Dinour and Davidovits. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pediatrics
Gurevich, Evgenia
Levi, Shelly
Borovitz, Yael
Alfandary, Hadas
Ganon, Liat
Dinour, Dganit
Davidovits, Miriam
Childhood Hypercalciuric Hypercalcemia With Elevated Vitamin D and Suppressed Parathyroid Hormone: Long-Term Follow Up
title Childhood Hypercalciuric Hypercalcemia With Elevated Vitamin D and Suppressed Parathyroid Hormone: Long-Term Follow Up
title_full Childhood Hypercalciuric Hypercalcemia With Elevated Vitamin D and Suppressed Parathyroid Hormone: Long-Term Follow Up
title_fullStr Childhood Hypercalciuric Hypercalcemia With Elevated Vitamin D and Suppressed Parathyroid Hormone: Long-Term Follow Up
title_full_unstemmed Childhood Hypercalciuric Hypercalcemia With Elevated Vitamin D and Suppressed Parathyroid Hormone: Long-Term Follow Up
title_short Childhood Hypercalciuric Hypercalcemia With Elevated Vitamin D and Suppressed Parathyroid Hormone: Long-Term Follow Up
title_sort childhood hypercalciuric hypercalcemia with elevated vitamin d and suppressed parathyroid hormone: long-term follow up
topic Pediatrics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631469/
https://www.ncbi.nlm.nih.gov/pubmed/34858904
http://dx.doi.org/10.3389/fped.2021.752312
work_keys_str_mv AT gurevichevgenia childhoodhypercalciurichypercalcemiawithelevatedvitamindandsuppressedparathyroidhormonelongtermfollowup
AT levishelly childhoodhypercalciurichypercalcemiawithelevatedvitamindandsuppressedparathyroidhormonelongtermfollowup
AT borovitzyael childhoodhypercalciurichypercalcemiawithelevatedvitamindandsuppressedparathyroidhormonelongtermfollowup
AT alfandaryhadas childhoodhypercalciurichypercalcemiawithelevatedvitamindandsuppressedparathyroidhormonelongtermfollowup
AT ganonliat childhoodhypercalciurichypercalcemiawithelevatedvitamindandsuppressedparathyroidhormonelongtermfollowup
AT dinourdganit childhoodhypercalciurichypercalcemiawithelevatedvitamindandsuppressedparathyroidhormonelongtermfollowup
AT davidovitsmiriam childhoodhypercalciurichypercalcemiawithelevatedvitamindandsuppressedparathyroidhormonelongtermfollowup